The Defense Ministry-run Israel Institute for Biological Research (IIBR) announced Monday that it had inked a memorandum of understanding with the Nasdaq-traded NRx Pharmaceuticals to complete the clinical trials of its homegrown COVID-19 vaccine. The Times of Israel news agency reported it.
NRx Pharmaceuticals will send the vaccine, known as Brilife, to third-stage clinical trials, which will be conducted on tens of thousands of volunteers in Georgia, Ukraine, and Israel, the Defense Ministry informed.
Clinical trials of the Brilife coronavirus vaccine began on November 1, 2020. The Israeli vaccine is still deep in the trial phase. In December, the Institute for Biological Research successfully completed the first stage of testing and started the second phase, which has been ongoing.
As reported before, Israel will offer a third dose of the Pfizer vaccine to adults with a weak immune system. The third dose for the general public is still being considered.
About half of the 46 patients presently hospitalized in Israel in severe condition are vaccinated, and the majority are from risk groups, according to the health authorities. About 5.7 million out of Israel's 9.3 population has received at least one dose, Reuters reported.